Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Primer of Neuroimmunological DiseaseMultiple Sclerosis Therapy

A Primer of Neuroimmunological Disease: Multiple Sclerosis Therapy [The history of multiple sclerosis therapy is generally one of futility, consisting of many far-fetched remedies, some of which have been painful or harmful or both. This is not surprising given the variability of the disease among patients, and even within the same patients, and considering the relative inability of current therapy to reverse the disease. However, significant advances have been made in MS therapy, which have made McAlpine’s pessimistic statement in 1965 outdated. The pessimism of previous times has been replaced by a flurry of attempts to optimize modern clinical trial design to identify effective treatments. These attempts, which have come from a massive amount of investment by pharmaceutical companies and the extensive efforts of neurologists and allied health care workers, have led to the discovery of many effective therapies. These therapies can be divided into two general categories. This chapter first covers “disease-modifying drugs (DMDs),” therapies which affect the underlying disease process. Next “symptomatic therapies” are discussed, including life-style changes which can benefit the patient.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A Primer of Neuroimmunological DiseaseMultiple Sclerosis Therapy

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/a-primer-of-neuroimmunological-disease-multiple-sclerosis-therapy-6YW7QJbIFZ
Publisher
Springer US
Copyright
© Springer Science+Business Media, LLC 2012
ISBN
978-1-4614-2187-0
Pages
69 –81
DOI
10.1007/978-1-4614-2188-7_7
Publisher site
See Chapter on Publisher Site

Abstract

[The history of multiple sclerosis therapy is generally one of futility, consisting of many far-fetched remedies, some of which have been painful or harmful or both. This is not surprising given the variability of the disease among patients, and even within the same patients, and considering the relative inability of current therapy to reverse the disease. However, significant advances have been made in MS therapy, which have made McAlpine’s pessimistic statement in 1965 outdated. The pessimism of previous times has been replaced by a flurry of attempts to optimize modern clinical trial design to identify effective treatments. These attempts, which have come from a massive amount of investment by pharmaceutical companies and the extensive efforts of neurologists and allied health care workers, have led to the discovery of many effective therapies. These therapies can be divided into two general categories. This chapter first covers “disease-modifying drugs (DMDs),” therapies which affect the underlying disease process. Next “symptomatic therapies” are discussed, including life-style changes which can benefit the patient.]

Published: Jan 17, 2012

Keywords: Experimental Autoimmune Encephalomyelitis; Botulinum Toxin; Progressive Multifocal Leukoencephalopathy; Glatiramer Acetate; Progressive Multifocal Leukoencephalopathy

There are no references for this article.